Zepp Health (ZEPP) Q1 2026 earnings review
Top-Line Growth Masks A Breakdown In Cost Discipline
Zepp Health delivered 33.8% YoY revenue growth in Q1 2026, achieving $51.5M. While the top-line recovery from early 2025 seems intact, the profitability narrative is unravelling. Management previously promised a strict adjusted operating expense run-rate of ~$25M-$27M; instead, Q1 2026 adjusted OpEx ballooned to $35.7M. Consequently, adjusted operating losses remained heavy at $16.3M. Compounding this margin pressure is a severely decelerating Q2 revenue guidance of just 6-14% YoY growth, suggesting the Amazfit turnaround momentum is rapidly cooling off.
🐂 Bull Case
The shift toward higher-end devices is materializing. Premium T-Rex models (Pro and Ultra) accounted for nearly 50% of the T-Rex family unit sales in March and April, indicating users are successfully moving up the value ladder.
Securing an exclusive 3-year global partnership with HYROX moves Zepp from a regional player to a global performance brand, giving direct access to a highly engaged fitness network and driving credibility.
🐻 Bear Case
The return to profitability was predicated on capping OpEx at $25M/quarter. Surging past $35M in Q1 entirely undermines the operating leverage thesis.
Q2 2026 revenue guidance implies just 10% YoY growth at the midpoint, a severe drop from the 30-70% growth rates enjoyed in late 2025.
⚖️ Verdict: 🔴
Bearish. A hardware company posting an adjusted operating loss equivalent to 31% of its revenue, while simultaneously breaking its own cost-cutting promises and guiding for a sharp growth deceleration, warrants significant caution.
Key Themes
The $25M OpEx Promise is Broken
Throughout 2025, management repeatedly anchored investors to a target adjusted operating expense run-rate of $25M-$27M to achieve profitability. In Q1 2026, adjusted OpEx came in at $35.7M (up $4.2M YoY and only slightly down from Q4's $37.1M). Management blamed RMB appreciation, e-commerce channel fees ($1.4M), and front-loaded marketing for CES/HYROX. Regardless of the reasons, the company is failing to demonstrate operating leverage as it scales.
Growth Momentum is Decelerating Rapidly
Zepp is guiding for Q2 2026 revenue of $63.0M-$68.0M, or 6-14% YoY growth. This is a massive deceleration from the 46% growth achieved in Q2 2025, and sequential drop from Q1's 33.8%. The 'turnaround' momentum appears to be normalizing much faster than expected.
Macro Headwinds Biting Gross Margins
Gross margin contracted sequentially from 40.4% in Q4 to 37.7% in Q1. While partly due to standard entry-level product refreshes, management explicitly called out elevated memory component costs and RMB appreciation against the USD as pressures. With the majority of OpEx denominated in RMB, further appreciation will double-down on profitability constraints.
Premium Product Adoption Showing Resilience
Despite margin pressures on the low end, the premium strategy is working. The newly launched Cheetah 2 Pro/Ultra and Amazfit Balance 3 are successfully targeting niche, high-value athletes (marathoners, trail runners). T-Rex Pro and Ultra models capturing ~50% of the T-Rex family sales mix is a strong proof point for ASP expansion.
Deepening HYROX Integration
Upgrading the HYROX partnership to an exclusive 3-year global deal is a strategic win. It moves the brand past basic sponsorships and embeds Zepp tech into the actual training ecosystem of gyms and coaches globally, acting as a highly targeted B2B2C customer acquisition channel.
Software Ecosystem & Hybrid AI Innovation
Zepp continues to shift from pure hardware to an ecosystem player. The introduction of HybridCharge Energy Intelligence and BioCharge in the Zepp App integrates Training Load and recovery data. These AI-driven features (built on the Zepp OS foundation) are critical for improving user retention and competing with Garmin in the serious athlete segment.
Other KPIs
Down $10M from $72.8M at the end of 2025. This is a positive indicator of working capital discipline, especially given management noted they made 'strategic risk purchases of key components for the future' (likely memory chips). Lower inventory reduces the risk of margin-crushing clearance sales later in the year.
A slight improvement from a $18.1M loss in Q1 2025, but a massive reversal from the operating breakeven achieved in Q3 2025. Elevated R&D ($13.1M) and Sales & Marketing ($16.6M) entirely consumed the $19.4M in gross profit.
Total debt remains relatively stable, but there is a noticeable shift in the mix. Due to accounting classification, borrowings previously maturing in late 2026/2027 shifted to short-term, pushing short-term bank borrowings and notes payable up. While the company has retired $46.4M since early 2023, the heavy short-term load requires monitoring.
Guidance
Decelerating. Implies a YoY growth rate of 6% to 14%. This represents a sharp drop-off from the 33.8% YoY growth in Q1 and the 46.2% growth in Q2 2025. Management attributes this to 'normal shipment timing and product launch phasing', but the magnitude of the slowdown suggests core demand may be softening.
Key Questions
Operating Expense Trajectory
You previously committed to bringing operating expenses down to a $25-27 million quarterly run rate. Q1 adjusted OpEx was $35.7 million. Is the $25 million target completely abandoned, and what is the realistic structural cost base going forward?
Q2 Deceleration Drivers
Q2 guidance of 6-14% growth is a steep deceleration from recent quarters. How much of this is due to tough YoY comps versus actual demand softening or delayed product launches?
Memory Chip Cost Mitigation
With memory component costs elevated and pressuring gross margins, how much pricing power do you actually have to pass these costs onto consumers with the new Cheetah and Balance lines, without sacrificing volume?
RMB Exposure
Given the highlighted headwind from RMB appreciation on operating expenses, what hedging strategies are currently in place for H2 2026?